Journal article

Systemic Therapy for Melanoma: ASCO Guideline

Rahul Seth, Hans Messersmith, Varinder Kaur, John M Kirkwood, Ragini Kudchadkar, Jennifer Leigh McQuade, Anthony Provenzano, Umang Swami, Jeffrey Weber, Krishna C Alluri, Sanjiv Agarwala, Paolo A Ascierto, Michael B Atkins, Nancy Davis, Marc S Ernstoff, Mark B Faries, Jason S Gold, Samantha Guild, David E Gyorki, Nikhil I Khushalani Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020


PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS: A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF-mutant disease. No recommendation..

View full abstract